Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 12, 2018

Primary Completion Date

June 12, 2019

Study Completion Date

June 12, 2019

Conditions
Parkinson Disease
Interventions
DRUG

Mesdopetam (IRL790)

Mesdopetam (IRL790) capsule

Trial Locations (20)

Unknown

Sahlgrenska University hospital, Gothenburg

University hospital, Linköping

University hospital, Lund

Karolinska University hospital, Stockholm

Bristol Brain Centre, Southmead Hospital, Bristol

Fairfield General Hospital (Pennine Acute NHS Trust), Bury

Ninewells Hospital, Dundee

Lincoln County Hospital, Lincoln

Charing Cross Hospital, Imperial College Healthcare NHS Trust, London

The National Hospital of Neurology and Neurosurgery (UCL), London

Luton and Dunstable University Hospital NHS Foundation Trust, Luton

North Tyneside General Hospital, North Shields

Qeens' Medical Centre, Nottingham

John Radcliffe Hospital, Oxford

Peterborough City Hospital, Peterborough

Queens's Hospital, Romford

Royal Stoke University Hospital, Stoke-on-Trent

Torbay hospital, Torquay

Royal Cornwall Hospital, Truro

PL6 8DH

Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth

All Listed Sponsors
collaborator

The Clinical Trial Company

INDUSTRY

lead

Integrative Research Laboratories AB

INDUSTRY

NCT03368170 - Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia | Biotech Hunter | Biotech Hunter